- Home
- CHRS vs QSI Comparison
CHRS vs QSI Comparison
Compare CHRS & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | QSI |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | 145 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.5M | 184.2M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHRS | QSI |
|---|---|---|
| Price | $1.76 | $0.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.51 | $1.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.8M |
| Earning Date | 03-09-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 472.00 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $73.08 | N/A |
| Revenue Next Year | $30.94 | $618.07 |
| P/E Ratio | $1.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.79 |
| 52 Week High | $2.62 | $3.10 |
Technical Indicators
Market Signals| Indicator | CHRS | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 41.80 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.94 | $1.11 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 51.04 | 25.91 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.